Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Elafibranor 120 mg in Healthy Elderly vs Young Adults
NCT04171752Phase 1Completed
- Sponsor
- Genfit
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elafibranor in Nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) (2 arms), sponsored by Genfit. Primary endpoints: Area Under the Curve and Maximum Plasma Concentration. Started Nov 2019; status: completed.
02
Drugs
elafibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04171752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171752.